IL105481A - Phenyl isoxazole sulfonamide derivatives and endothelin antagonist pharmaceutical compositions containing the same - Google Patents
Phenyl isoxazole sulfonamide derivatives and endothelin antagonist pharmaceutical compositions containing the sameInfo
- Publication number
- IL105481A IL105481A IL10548193A IL10548193A IL105481A IL 105481 A IL105481 A IL 105481A IL 10548193 A IL10548193 A IL 10548193A IL 10548193 A IL10548193 A IL 10548193A IL 105481 A IL105481 A IL 105481A
- Authority
- IL
- Israel
- Prior art keywords
- isoxazolyl
- dimethyl
- sulfonamide
- compound
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 239000002308 endothelin receptor antagonist Substances 0.000 title description 3
- IHWKKPLIRGORJX-UHFFFAOYSA-N n-phenyl-1,2-oxazole-3-sulfonamide Chemical class C1=CON=C1S(=O)(=O)NC1=CC=CC=C1 IHWKKPLIRGORJX-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 105
- -1 cycloalkenylalkyl Chemical group 0.000 claims abstract description 92
- 125000003118 aryl group Chemical group 0.000 claims abstract description 63
- 239000001257 hydrogen Substances 0.000 claims abstract description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 58
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 51
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 43
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 39
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 35
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 33
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 29
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 16
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 16
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 16
- 125000004104 aryloxy group Chemical group 0.000 claims abstract description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 11
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 6
- 229940124530 sulfonamide Drugs 0.000 claims description 29
- 229920006395 saturated elastomer Polymers 0.000 claims description 21
- 125000004450 alkenylene group Chemical group 0.000 claims description 20
- 125000002947 alkylene group Chemical group 0.000 claims description 19
- 239000004305 biphenyl Substances 0.000 claims description 14
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 235000010290 biphenyl Nutrition 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- GDARDKVQKGHHRI-UHFFFAOYSA-N 2-(2-aminophenyl)-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C(=CC=CC=2)N)=C1C GDARDKVQKGHHRI-UHFFFAOYSA-N 0.000 claims description 3
- FICDMFJBLNFMAR-UHFFFAOYSA-N 2-bromo-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)Br)=C1C FICDMFJBLNFMAR-UHFFFAOYSA-N 0.000 claims description 3
- 125000004419 alkynylene group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- HMZBPKJDXIHPEG-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-nitrobenzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)[N+]([O-])=O)=C1C HMZBPKJDXIHPEG-UHFFFAOYSA-N 0.000 claims description 3
- XANLXADXCDHWKP-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-phenoxybenzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)OC=2C=CC=CC=2)=C1C XANLXADXCDHWKP-UHFFFAOYSA-N 0.000 claims description 3
- SLBYWDJLJLBXGV-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-phenylbenzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C=CC=CC=2)=C1C SLBYWDJLJLBXGV-UHFFFAOYSA-N 0.000 claims description 3
- ANCMRDKQGAORLD-UHFFFAOYSA-N n-[3-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]-4-methylphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C(S(=O)(=O)NC2=C(C(C)=NO2)C)=C1 ANCMRDKQGAORLD-UHFFFAOYSA-N 0.000 claims description 3
- XIOWPJCHSRNYQG-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C=CC(=CC=2)C(C)(C)C)=C1C XIOWPJCHSRNYQG-UHFFFAOYSA-N 0.000 claims description 2
- FAJJTSBWHDOEGD-UHFFFAOYSA-N 2-(dimethylamino)-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CN(C)C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 FAJJTSBWHDOEGD-UHFFFAOYSA-N 0.000 claims description 2
- WXBXZJWIPDOUMI-UHFFFAOYSA-N 2-amino-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)N)=C1C WXBXZJWIPDOUMI-UHFFFAOYSA-N 0.000 claims description 2
- RRELFOAIHGTXMK-UHFFFAOYSA-N 4-amino-2-fluoro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(N)=CC=2)F)=N1 RRELFOAIHGTXMK-UHFFFAOYSA-N 0.000 claims description 2
- UXGOVZWJTNZGPA-UHFFFAOYSA-N 5-amino-n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-methylbenzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=C(N)C=2)C)=C1C UXGOVZWJTNZGPA-UHFFFAOYSA-N 0.000 claims description 2
- IRWKUXXPQOGSND-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-(4-methoxyphenyl)benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 IRWKUXXPQOGSND-UHFFFAOYSA-N 0.000 claims description 2
- DYLKKVMDOFKPBE-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-(4-propan-2-yloxyphenyl)benzenesulfonamide Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 DYLKKVMDOFKPBE-UHFFFAOYSA-N 0.000 claims description 2
- PEIJQOZFRKLCAI-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[2-hydroxy-4-(2-methylpropyl)phenyl]benzenesulfonamide Chemical compound OC1=CC(CC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 PEIJQOZFRKLCAI-UHFFFAOYSA-N 0.000 claims description 2
- RZRSCFPIKIODFH-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-fluorobenzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)F)=C1C RZRSCFPIKIODFH-UHFFFAOYSA-N 0.000 claims description 2
- ZQUFTQSIAVTDPF-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-naphthalen-1-ylbenzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C3=CC=CC=C3C=CC=2)=C1C ZQUFTQSIAVTDPF-UHFFFAOYSA-N 0.000 claims description 2
- APFKWATYQZKXFJ-UHFFFAOYSA-N n-[3-[2-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]phenyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C(=CC=CC=2)S(=O)(=O)NC2=C(C(C)=NO2)C)=C1 APFKWATYQZKXFJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- JNMBQUUVMUDBGI-UHFFFAOYSA-N 2-(3-aminophenyl)-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C=C(N)C=CC=2)=C1C JNMBQUUVMUDBGI-UHFFFAOYSA-N 0.000 claims 1
- RSFKORNHHZWOJK-UHFFFAOYSA-N 5-amino-n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(2-methylpropyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC=C(N)C=C1S(=O)(=O)NC1=C(C)C(C)=NO1 RSFKORNHHZWOJK-UHFFFAOYSA-N 0.000 claims 1
- USQCUKQZXOWUDF-YWZLYKJASA-N 6-chloro-n-[(3s)-1-[(2s)-1-(4-methyl-5-oxo-1,4-diazepan-1-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide Chemical compound O=C([C@@H](N1C([C@@H](NS(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1)=O)C)N1CCN(C)C(=O)CC1 USQCUKQZXOWUDF-YWZLYKJASA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZYLOLYHYEVOCLC-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-(4-phenylmethoxyphenyl)benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)=C1C ZYLOLYHYEVOCLC-UHFFFAOYSA-N 0.000 claims 1
- BBNRKSPDJHJZHA-UHFFFAOYSA-N n-(4,5-dimethyl-1,2-oxazol-3-yl)-2-[4-(2-methylpropyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C BBNRKSPDJHJZHA-UHFFFAOYSA-N 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 abstract description 2
- 108050009340 Endothelin Proteins 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 329
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 185
- 229940126062 Compound A Drugs 0.000 description 116
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 116
- 239000000243 solution Substances 0.000 description 111
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 108
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 99
- 239000000203 mixture Substances 0.000 description 87
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 79
- 229910001868 water Inorganic materials 0.000 description 76
- 239000007787 solid Substances 0.000 description 71
- 239000000741 silica gel Substances 0.000 description 57
- 229910002027 silica gel Inorganic materials 0.000 description 57
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 47
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 47
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 47
- 238000004458 analytical method Methods 0.000 description 46
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 38
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 36
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 34
- 238000004587 chromatography analysis Methods 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 239000012267 brine Substances 0.000 description 27
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 26
- 238000010992 reflux Methods 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 21
- 239000000377 silicon dioxide Substances 0.000 description 20
- 239000000284 extract Substances 0.000 description 19
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 19
- 235000019341 magnesium sulphate Nutrition 0.000 description 19
- 238000002425 crystallisation Methods 0.000 description 18
- 230000008025 crystallization Effects 0.000 description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 18
- 229960000583 acetic acid Drugs 0.000 description 17
- 229910052786 argon Inorganic materials 0.000 description 17
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 239000000725 suspension Substances 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- 239000005457 ice water Substances 0.000 description 12
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 12
- PYNDWPFZDQONDV-UHFFFAOYSA-N 3,4-dimethyl-1,2-oxazol-5-amine Chemical compound CC1=NOC(N)=C1C PYNDWPFZDQONDV-UHFFFAOYSA-N 0.000 description 11
- 239000012362 glacial acetic acid Substances 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000012259 ether extract Substances 0.000 description 9
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000006286 aqueous extract Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 241000400611 Eucalyptus deanei Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- RHFWLPWDOYJEAL-UHFFFAOYSA-N 1,2-oxazol-3-amine Chemical compound NC=1C=CON=1 RHFWLPWDOYJEAL-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- YZSPHVWALUJQNK-UHFFFAOYSA-N [4-(2-methylpropyl)phenyl]boronic acid Chemical compound CC(C)CC1=CC=C(B(O)O)C=C1 YZSPHVWALUJQNK-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000003416 antiarrhythmic agent Substances 0.000 description 3
- 150000001502 aryl halides Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 239000004533 oil dispersion Substances 0.000 description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 125000000565 sulfonamide group Chemical group 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- VFPWGZNNRSQPBT-UHFFFAOYSA-N 2-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1Br VFPWGZNNRSQPBT-UHFFFAOYSA-N 0.000 description 2
- 108010058207 Anistreplase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 2
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- 239000012351 deprotecting agent Substances 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- JKGIOCXEAJIYNE-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-(2-nitrophenyl)benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C(=CC=CC=2)[N+]([O-])=O)=C1C JKGIOCXEAJIYNE-UHFFFAOYSA-N 0.000 description 2
- BWTQPWDURQZRKQ-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(2-methylpropyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 BWTQPWDURQZRKQ-UHFFFAOYSA-N 0.000 description 2
- BKAUHGLDNGNVCA-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(propan-2-ylamino)phenyl]benzenesulfonamide Chemical compound C1=CC(NC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 BKAUHGLDNGNVCA-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 150000003461 sulfonyl halides Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- HHBXWXJLQYJJBW-UHFFFAOYSA-M triphenyl(propan-2-yl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C(C)C)C1=CC=CC=C1 HHBXWXJLQYJJBW-UHFFFAOYSA-M 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- DIRRKLFMHQUJCM-UHFFFAOYSA-N (2-aminophenyl)boronic acid Chemical compound NC1=CC=CC=C1B(O)O DIRRKLFMHQUJCM-UHFFFAOYSA-N 0.000 description 1
- SFUIGUOONHIVLG-UHFFFAOYSA-N (2-nitrophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1[N+]([O-])=O SFUIGUOONHIVLG-UHFFFAOYSA-N 0.000 description 1
- NVXFXLSOGLFXKQ-JMSVASOKSA-N (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- RMYMVZYEHYEORU-UHFFFAOYSA-N (3-bromo-2-methylpropyl)benzene Chemical compound BrCC(C)CC1=CC=CC=C1 RMYMVZYEHYEORU-UHFFFAOYSA-N 0.000 description 1
- UGZUUTHZEATQAM-UHFFFAOYSA-N (4-butylphenyl)boronic acid Chemical compound CCCCC1=CC=C(B(O)O)C=C1 UGZUUTHZEATQAM-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- DMJHEIDWSIAXCS-UHFFFAOYSA-N (4-phenylmethoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OCC1=CC=CC=C1 DMJHEIDWSIAXCS-UHFFFAOYSA-N 0.000 description 1
- CJUHQADBFQRIMC-UHFFFAOYSA-N (4-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC=C(B(O)O)C=C1 CJUHQADBFQRIMC-UHFFFAOYSA-N 0.000 description 1
- WLCGYIWOKVWFLB-UHFFFAOYSA-N (4-propylphenyl)boronic acid Chemical compound CCCC1=CC=C(B(O)O)C=C1 WLCGYIWOKVWFLB-UHFFFAOYSA-N 0.000 description 1
- MNJYZNVROSZZQC-UHFFFAOYSA-N (4-tert-butylphenyl)boronic acid Chemical compound CC(C)(C)C1=CC=C(B(O)O)C=C1 MNJYZNVROSZZQC-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- DHQINUJUNGHFJR-UHFFFAOYSA-N 1-(2-methylprop-1-enyl)-3-nitrobenzene Chemical compound CC(C)=CC1=CC=CC([N+]([O-])=O)=C1 DHQINUJUNGHFJR-UHFFFAOYSA-N 0.000 description 1
- ZSKXYSCQDWAUCM-UHFFFAOYSA-N 1-(chloromethyl)-2-dodecylbenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1CCl ZSKXYSCQDWAUCM-UHFFFAOYSA-N 0.000 description 1
- IFYLTXNCFVRALQ-UHFFFAOYSA-N 1-[6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]pyrrolidine-2-carboxylic acid Chemical compound C1CCC(C(O)=O)N1C(=O)C(CCCCN)OP(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-UHFFFAOYSA-N 0.000 description 1
- YSJTXBKDIUSLGN-UHFFFAOYSA-N 1-bromo-3-(2-methylpropyl)benzene Chemical compound CC(C)CC1=CC=CC(Br)=C1 YSJTXBKDIUSLGN-UHFFFAOYSA-N 0.000 description 1
- CTPUUDQIXKUAMO-UHFFFAOYSA-N 1-bromo-3-iodobenzene Chemical compound BrC1=CC=CC(I)=C1 CTPUUDQIXKUAMO-UHFFFAOYSA-N 0.000 description 1
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
- FMAIALVMJJUXSB-UHFFFAOYSA-N 1-bromo-4-(2-methylpropoxy)benzene Chemical compound CC(C)COC1=CC=C(Br)C=C1 FMAIALVMJJUXSB-UHFFFAOYSA-N 0.000 description 1
- BRGVKVZXDWGJBX-UHFFFAOYSA-N 1-bromo-4-butylbenzene Chemical compound CCCCC1=CC=C(Br)C=C1 BRGVKVZXDWGJBX-UHFFFAOYSA-N 0.000 description 1
- OUQSGILAXUXMGI-UHFFFAOYSA-N 1-bromo-4-phenylmethoxybenzene Chemical compound C1=CC(Br)=CC=C1OCC1=CC=CC=C1 OUQSGILAXUXMGI-UHFFFAOYSA-N 0.000 description 1
- MPAOOLLBWUEXOM-UHFFFAOYSA-N 1-bromo-4-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=C(Br)C=C1 MPAOOLLBWUEXOM-UHFFFAOYSA-N 0.000 description 1
- XHCAGOVGSDHHNP-UHFFFAOYSA-N 1-bromo-4-tert-butylbenzene Chemical compound CC(C)(C)C1=CC=C(Br)C=C1 XHCAGOVGSDHHNP-UHFFFAOYSA-N 0.000 description 1
- GUBSYZAKSWLNLD-UHFFFAOYSA-N 1-fluoro-2-(2-methylprop-1-enyl)benzene Chemical compound CC(C)=CC1=CC=CC=C1F GUBSYZAKSWLNLD-UHFFFAOYSA-N 0.000 description 1
- MNVZZSJFWAZZGZ-UHFFFAOYSA-N 1-fluoro-2-(2-methylpropyl)benzene Chemical compound CC(C)CC1=CC=CC=C1F MNVZZSJFWAZZGZ-UHFFFAOYSA-N 0.000 description 1
- HWINBBUYLKWIBO-UHFFFAOYSA-N 1-methoxy-3-propan-2-ylbenzene Chemical compound COC1=CC=CC(C(C)C)=C1 HWINBBUYLKWIBO-UHFFFAOYSA-N 0.000 description 1
- UVGFBAJQJIDKKI-UHFFFAOYSA-N 2,2-dimethyl-n-[3-(2-methylprop-1-enyl)phenyl]propanamide Chemical compound CC(C)=CC1=CC=CC(NC(=O)C(C)(C)C)=C1 UVGFBAJQJIDKKI-UHFFFAOYSA-N 0.000 description 1
- PUFCBLZWFRZZRG-UHFFFAOYSA-N 2,2-dimethyl-n-[3-(2-methylpropyl)phenyl]propanamide Chemical compound CC(C)CC1=CC=CC(NC(=O)C(C)(C)C)=C1 PUFCBLZWFRZZRG-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- IGWBGJHGRLFVKY-UHFFFAOYSA-N 2-(2-aminophenyl)-n-(3,4-dimethyl-1,2-oxazol-5-yl)-n-(2-methoxyethoxymethyl)benzenesulfonamide Chemical compound C=1C=CC=C(C=2C(=CC=CC=2)N)C=1S(=O)(=O)N(COCCOC)C=1ON=C(C)C=1C IGWBGJHGRLFVKY-UHFFFAOYSA-N 0.000 description 1
- PUVGBKOHDJUFRZ-UHFFFAOYSA-N 2-(2-pyridin-3-ylpiperidin-1-yl)acetonitrile Chemical compound N#CCN1CCCCC1C1=CC=CN=C1 PUVGBKOHDJUFRZ-UHFFFAOYSA-N 0.000 description 1
- FCHKQXOKZYCRKJ-UHFFFAOYSA-N 2-(4-aminophenyl)-n-(3,4-dimethyl-1,2-oxazol-5-yl)-n-(2-methoxyethoxymethyl)benzenesulfonamide Chemical compound C=1C=CC=C(C=2C=CC(N)=CC=2)C=1S(=O)(=O)N(COCCOC)C=1ON=C(C)C=1C FCHKQXOKZYCRKJ-UHFFFAOYSA-N 0.000 description 1
- KOFDUFCOGWCINH-UHFFFAOYSA-N 2-(4-butylphenyl)-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound C1=CC(CCCC)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 KOFDUFCOGWCINH-UHFFFAOYSA-N 0.000 description 1
- ZIZGWNOAHUCACM-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1S(Cl)(=O)=O ZIZGWNOAHUCACM-UHFFFAOYSA-N 0.000 description 1
- DHAHVLSQWCHUOO-UHFFFAOYSA-N 2-[2-(dimethylamino)phenyl]-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 DHAHVLSQWCHUOO-UHFFFAOYSA-N 0.000 description 1
- GZOXZNVVYKXRRQ-UHFFFAOYSA-N 2-[2-amino-4-(2-methylpropyl)phenyl]-n-(3,4-dimethyl-1,2-oxazol-5-yl)-n-(2-methoxyethoxymethyl)benzenesulfonamide Chemical compound C=1C=CC=C(C=2C(=CC(CC(C)C)=CC=2)N)C=1S(=O)(=O)N(COCCOC)C=1ON=C(C)C=1C GZOXZNVVYKXRRQ-UHFFFAOYSA-N 0.000 description 1
- OZDIAVKCLFSBME-UHFFFAOYSA-N 2-[2-amino-4-(2-methylpropyl)phenyl]-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound NC1=CC(CC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 OZDIAVKCLFSBME-UHFFFAOYSA-N 0.000 description 1
- IRGOLZQDQJNOFK-UHFFFAOYSA-N 2-[3-(dimethylamino)phenyl]-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CN(C)C1=CC=CC(C=2C(=CC=CC=2)S(=O)(=O)NC2=C(C(C)=NO2)C)=C1 IRGOLZQDQJNOFK-UHFFFAOYSA-N 0.000 description 1
- PNIMKAGRLWRIQD-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]-n-(4,5,6,7-tetrahydro-2,1-benzoxazol-3-yl)benzenesulfonamide Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C2CCCCC2=NO1 PNIMKAGRLWRIQD-UHFFFAOYSA-N 0.000 description 1
- WYHUXSLJAFMVPL-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]benzenesulfonic acid Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC=CC=C1S(O)(=O)=O WYHUXSLJAFMVPL-UHFFFAOYSA-N 0.000 description 1
- RWQZTLOPSMHBQW-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]-n-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 RWQZTLOPSMHBQW-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- FKCPLYRCCWPTJX-UHFFFAOYSA-N 2-[[[4-[2-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]phenyl]phenyl]-propan-2-ylcarbamoyl]amino]-4-methylpentanoic acid Chemical compound C1=CC(N(C(C)C)C(=O)NC(CC(C)C)C(O)=O)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 FKCPLYRCCWPTJX-UHFFFAOYSA-N 0.000 description 1
- NRNTWMTVYWBKSM-UHFFFAOYSA-N 2-bromo-4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C(Br)=C1 NRNTWMTVYWBKSM-UHFFFAOYSA-N 0.000 description 1
- FOZCQVAYHBVJFA-UHFFFAOYSA-N 2-bromo-n-(3,4-dimethyl-1,2-oxazol-5-yl)-4-methoxy-n-(2-methoxyethoxymethyl)benzenesulfonamide Chemical compound C=1C=C(OC)C=C(Br)C=1S(=O)(=O)N(COCCOC)C=1ON=C(C)C=1C FOZCQVAYHBVJFA-UHFFFAOYSA-N 0.000 description 1
- PGCXWVCOKUSVNB-UHFFFAOYSA-N 2-bromo-n-(3,4-dimethyl-1,2-oxazol-5-yl)-4-methoxybenzenesulfonamide Chemical compound BrC1=CC(OC)=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 PGCXWVCOKUSVNB-UHFFFAOYSA-N 0.000 description 1
- YSFGGXNLZUSHHS-UHFFFAOYSA-N 2-bromobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1Br YSFGGXNLZUSHHS-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- FJVZVTWCAGCLCS-UHFFFAOYSA-N 2-chloro-6-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC(Cl)=C1S(Cl)(=O)=O FJVZVTWCAGCLCS-UHFFFAOYSA-N 0.000 description 1
- SQRCNKWHGRNUAM-UHFFFAOYSA-N 2-chloro-n-(3,4-dimethyl-1,2-oxazol-5-yl)-6-methylbenzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2C)Cl)=C1C SQRCNKWHGRNUAM-UHFFFAOYSA-N 0.000 description 1
- ZSZKAQCISWFDCQ-UHFFFAOYSA-N 2-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC=C1S(Cl)(=O)=O ZSZKAQCISWFDCQ-UHFFFAOYSA-N 0.000 description 1
- WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
- NMFFUUFPJJOWHK-UHFFFAOYSA-N 2-phenoxyaniline Chemical compound NC1=CC=CC=C1OC1=CC=CC=C1 NMFFUUFPJJOWHK-UHFFFAOYSA-N 0.000 description 1
- MFBATEXBHGBONO-UHFFFAOYSA-N 2-phenoxybenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1OC1=CC=CC=C1 MFBATEXBHGBONO-UHFFFAOYSA-N 0.000 description 1
- DJPFVWLKONDDNE-UHFFFAOYSA-N 2-phenylaniline;2-phenylbenzenesulfonyl chloride Chemical group NC1=CC=CC=C1C1=CC=CC=C1.ClS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 DJPFVWLKONDDNE-UHFFFAOYSA-N 0.000 description 1
- QEDRUXIMTJVXFL-UHFFFAOYSA-N 2-propan-2-ylbenzenethiol Chemical compound CC(C)C1=CC=CC=C1S QEDRUXIMTJVXFL-UHFFFAOYSA-N 0.000 description 1
- MJUDRIFRJLXJEX-UHFFFAOYSA-N 3-(2-methylprop-1-enyl)aniline Chemical compound CC(C)=CC1=CC=CC(N)=C1 MJUDRIFRJLXJEX-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- NRYUCAPNMJIWFE-UHFFFAOYSA-N 3-methyl-4-nitro-1,2-oxazol-5-amine Chemical compound CC1=NOC(N)=C1[N+]([O-])=O NRYUCAPNMJIWFE-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- CRGVRAUXLNRYKJ-UHFFFAOYSA-N 4,5,6,7-tetrahydro-2,1-benzoxazol-3-amine Chemical compound C1CCCC2=C(N)ON=C21 CRGVRAUXLNRYKJ-UHFFFAOYSA-N 0.000 description 1
- VPANVNSDJSUFEF-UHFFFAOYSA-N 4,5-dimethyl-1,2-oxazol-3-amine Chemical compound CC=1ON=C(N)C=1C VPANVNSDJSUFEF-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JRLPTFYGXMPDHL-UHFFFAOYSA-N 4-acetamido-2-bromobenzenesulfonyl chloride Chemical compound CC(=O)NC1=CC=C(S(Cl)(=O)=O)C(Br)=C1 JRLPTFYGXMPDHL-UHFFFAOYSA-N 0.000 description 1
- SDBKITDRHHUZCB-UHFFFAOYSA-N 4-benzyl-3-methyl-1,2-oxazol-5-amine Chemical compound CC1=NOC(N)=C1CC1=CC=CC=C1 SDBKITDRHHUZCB-UHFFFAOYSA-N 0.000 description 1
- QPPCLNMOYHCXMS-UHFFFAOYSA-N 4-bromo-2-methoxybenzenesulfonyl chloride Chemical compound COC1=CC(Br)=CC=C1S(Cl)(=O)=O QPPCLNMOYHCXMS-UHFFFAOYSA-N 0.000 description 1
- BBUAVBFWIZNTOB-UHFFFAOYSA-N 4-bromo-n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-methoxybenzenesulfonamide Chemical compound COC1=CC(Br)=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 BBUAVBFWIZNTOB-UHFFFAOYSA-N 0.000 description 1
- GYNLTWUPSJGXFV-UHFFFAOYSA-N 4-methyl-1,2-oxazol-5-amine Chemical compound CC=1C=NOC=1N GYNLTWUPSJGXFV-UHFFFAOYSA-N 0.000 description 1
- PGHCZOLSJYBOFG-UHFFFAOYSA-N 5-acetamido-2-methylbenzenesulfonic acid Chemical class CC(=O)NC1=CC=C(C)C(S(O)(=O)=O)=C1 PGHCZOLSJYBOFG-UHFFFAOYSA-N 0.000 description 1
- BCGUUSFEJVCVLK-UHFFFAOYSA-N 5-acetamido-2-methylbenzenesulfonyl chloride Chemical compound CC(=O)NC1=CC=C(C)C(S(Cl)(=O)=O)=C1 BCGUUSFEJVCVLK-UHFFFAOYSA-N 0.000 description 1
- BRKFTWHPLMMNHF-UHFFFAOYSA-N 5-amino-2-methylbenzenesulfonic acid Chemical class CC1=CC=C(N)C=C1S(O)(=O)=O BRKFTWHPLMMNHF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 229910015446 B(OCH3)3 Inorganic materials 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000026005 Central nervous system vascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- NTHBRMLLSUXEEG-UHFFFAOYSA-N [2-fluoro-4-(2-methylpropyl)phenyl]boronic acid Chemical compound CC(C)CC1=CC=C(B(O)O)C(F)=C1 NTHBRMLLSUXEEG-UHFFFAOYSA-N 0.000 description 1
- UCIPLLNDFCCBAC-UHFFFAOYSA-N [4-(2-methylpropoxy)phenyl]boronic acid Chemical compound CC(C)COC1=CC=C(B(O)O)C=C1 UCIPLLNDFCCBAC-UHFFFAOYSA-N 0.000 description 1
- RIIPFHVHLXPMHQ-UHFFFAOYSA-N [4-(dimethylamino)phenyl]boronic acid Chemical compound CN(C)C1=CC=C(B(O)O)C=C1 RIIPFHVHLXPMHQ-UHFFFAOYSA-N 0.000 description 1
- HFPDWJMICZDKNO-UHFFFAOYSA-M [Br-].CCCC1=CC=C([Mg+])C=C1 Chemical compound [Br-].CCCC1=CC=C([Mg+])C=C1 HFPDWJMICZDKNO-UHFFFAOYSA-M 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000008148 cardioplegic solution Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- SSTQICMSRVMLQN-UHFFFAOYSA-N ethyl 2-isocyanato-4-methylpentanoate Chemical compound CCOC(=O)C(CC(C)C)N=C=O SSTQICMSRVMLQN-UHFFFAOYSA-N 0.000 description 1
- AINLNLOATKLFMW-UHFFFAOYSA-N ethyl 5-bromo-3-methyl-1,2-oxazole-4-carboxylate Chemical compound CCOC(=O)C=1C(C)=NOC=1Br AINLNLOATKLFMW-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000005171 halobenzenes Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 1
- DQDWATOXYCARFV-UHFFFAOYSA-M magnesium;2-methanidylpropane;bromide Chemical compound [Mg+2].[Br-].CC(C)[CH2-] DQDWATOXYCARFV-UHFFFAOYSA-M 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- KOIOXZPPAMBEIL-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-(4-methylphenyl)benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C=CC(C)=CC=2)=C1C KOIOXZPPAMBEIL-UHFFFAOYSA-N 0.000 description 1
- PTGBBGYJNDIZFK-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-(4-propylphenyl)benzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 PTGBBGYJNDIZFK-UHFFFAOYSA-N 0.000 description 1
- YWMJIHYZSISDHK-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1C YWMJIHYZSISDHK-UHFFFAOYSA-N 0.000 description 1
- ZBXVVTFXRMGBEE-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[2-fluoro-4-(2-methylpropyl)phenyl]benzenesulfonamide Chemical compound FC1=CC(CC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 ZBXVVTFXRMGBEE-UHFFFAOYSA-N 0.000 description 1
- LMIVZHGYWWZPOD-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(2-methylpropoxy)phenyl]benzenesulfonamide Chemical compound C1=CC(OCC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 LMIVZHGYWWZPOD-UHFFFAOYSA-N 0.000 description 1
- CWRJTQCWQJJTPF-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-propan-2-ylbenzenesulfonamide Chemical compound CC(C)C1=CC=CC=C1S(=O)(=O)NC1=C(C)C(C)=NO1 CWRJTQCWQJJTPF-UHFFFAOYSA-N 0.000 description 1
- KPYOOYQKINTMAO-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-5-methoxy-n-(2-methoxyethoxymethyl)-2-[4-(2-methylpropyl)phenyl]benzenesulfonamide Chemical compound C=1C(OC)=CC=C(C=2C=CC(CC(C)C)=CC=2)C=1S(=O)(=O)N(COCCOC)C=1ON=C(C)C=1C KPYOOYQKINTMAO-UHFFFAOYSA-N 0.000 description 1
- ZGKRVIAYOJYUBP-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-n-(2-methoxyethoxymethyl)-2-(2-nitrophenyl)benzenesulfonamide Chemical compound C=1C=CC=C(C=2C(=CC=CC=2)[N+]([O-])=O)C=1S(=O)(=O)N(COCCOC)C=1ON=C(C)C=1C ZGKRVIAYOJYUBP-UHFFFAOYSA-N 0.000 description 1
- PGIAVOKXQBPAGE-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-n-(2-methoxyethoxymethyl)-2-(4-propan-2-yloxyphenyl)benzenesulfonamide Chemical compound C=1C=CC=C(C=2C=CC(OC(C)C)=CC=2)C=1S(=O)(=O)N(COCCOC)C=1ON=C(C)C=1C PGIAVOKXQBPAGE-UHFFFAOYSA-N 0.000 description 1
- HOONKCULFMAHHT-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-n-(2-methoxyethoxymethyl)-2-naphthalen-1-ylbenzenesulfonamide Chemical compound C=1C=CC=C(C=2C3=CC=CC=C3C=CC=2)C=1S(=O)(=O)N(COCCOC)C=1ON=C(C)C=1C HOONKCULFMAHHT-UHFFFAOYSA-N 0.000 description 1
- XXHOHJTVFUJJMT-UHFFFAOYSA-N n-(3-bromophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(Br)=C1 XXHOHJTVFUJJMT-UHFFFAOYSA-N 0.000 description 1
- NRDNRKCJYHXRNQ-UHFFFAOYSA-N n-(3-methyl-4-nitro-1,2-oxazol-5-yl)-2-[4-(2-methylpropyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C([N+]([O-])=O)C(C)=NO1 NRDNRKCJYHXRNQ-UHFFFAOYSA-N 0.000 description 1
- NDZFZLQOTKAJTH-UHFFFAOYSA-N n-(4-benzyl-3-methyl-1,2-oxazol-5-yl)-2-[4-(2-methylpropyl)phenyl]benzenesulfonamide Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=C(CC=2C=CC=CC=2)C(C)=NO1 NDZFZLQOTKAJTH-UHFFFAOYSA-N 0.000 description 1
- HUMMCEUVDBVXTQ-UHFFFAOYSA-N naphthalen-1-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CC=CC2=C1 HUMMCEUVDBVXTQ-UHFFFAOYSA-N 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229950008492 pentopril Drugs 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87900092A | 1992-05-06 | 1992-05-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL105481A0 IL105481A0 (en) | 1993-08-18 |
| IL105481A true IL105481A (en) | 1996-12-05 |
Family
ID=25373236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10548193A IL105481A (en) | 1992-05-06 | 1993-04-21 | Phenyl isoxazole sulfonamide derivatives and endothelin antagonist pharmaceutical compositions containing the same |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0569193B1 (pl) |
| JP (1) | JP3286391B2 (pl) |
| KR (1) | KR100277454B1 (pl) |
| CN (1) | CN1066441C (pl) |
| AT (1) | ATE149155T1 (pl) |
| AU (1) | AU659545B2 (pl) |
| CA (1) | CA2095174A1 (pl) |
| CY (1) | CY2016A (pl) |
| DE (1) | DE69308229T2 (pl) |
| DK (1) | DK0569193T3 (pl) |
| ES (1) | ES2100459T3 (pl) |
| FI (1) | FI112655B (pl) |
| GR (1) | GR3023421T3 (pl) |
| HK (1) | HK98197A (pl) |
| HU (1) | HU218938B (pl) |
| IL (1) | IL105481A (pl) |
| MX (1) | MX9302618A (pl) |
| NO (1) | NO303065B1 (pl) |
| NZ (1) | NZ247440A (pl) |
| PL (1) | PL178165B1 (pl) |
| RU (1) | RU2133742C1 (pl) |
| ZA (1) | ZA932914B (pl) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124343A (en) * | 1919-01-27 | 2000-09-26 | Rhone-Poulenc Rorer Limited | Substituted phenyl compounds with a substituent having a thienyl ring |
| EP0301103A4 (en) * | 1987-02-09 | 1989-07-20 | Mitsui Petrochemical Ind | Sheet-like molding material and laminate for molding containing the material as one layer. |
| US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5736509A (en) * | 1990-12-14 | 1998-04-07 | Texas Biotechnology Corporation | Cyclic peptide surface feature mimics of endothelin |
| US5767310A (en) * | 1993-03-19 | 1998-06-16 | Merck & Co., Inc. | Phenoxyphenylacetic acid derivatives |
| CA2121724A1 (en) | 1993-04-21 | 1994-10-22 | Toshifumi Watanabe | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction |
| US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6030991A (en) * | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5686478A (en) * | 1993-07-20 | 1997-11-11 | Merck & Co. Inc. | Endothelin antagonists |
| ES2081250B1 (es) * | 1993-07-28 | 1996-10-16 | Squibb & Sons Inc | Antagonistas de endotelina a base de fenilsulfonamida. |
| US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
| JPH09504302A (ja) * | 1993-11-01 | 1997-04-28 | 日本チバガイギー株式会社 | エンドセリン・レセプター・アンタゴニスト |
| US5431842A (en) * | 1993-11-05 | 1995-07-11 | The Procter & Gamble Company | Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme |
| IL111959A (en) * | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
| GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
| GB9409618D0 (en) * | 1994-05-13 | 1994-07-06 | Zeneca Ltd | Pyridine derivatives |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
| US5538991A (en) * | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
| FR2724654B1 (fr) * | 1994-09-16 | 1997-12-12 | Roussel Uclaf | Nouveaux derives de l'acide gallique, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| FR2725988B1 (fr) * | 1994-10-24 | 1997-01-24 | Roussel Uclaf | Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| US5962682A (en) * | 1994-12-20 | 1999-10-05 | Hoffmann-La Roche Inc. | Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists |
| CA2168154A1 (en) * | 1995-02-06 | 1996-08-07 | Natesan Murugesan | Substituted biphenyl sulfonamide endothelin antagonists |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| DE19509950A1 (de) * | 1995-03-18 | 1996-09-19 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
| ES2201181T3 (es) * | 1995-04-04 | 2004-03-16 | Encysive Pharmaceuticals Inc. | Tienil-, furil-, pirrolil- y bifenilsulfonamidas y derivados de los mismos que modulan la actividad de endotelina. |
| US5739333A (en) * | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| AU7094996A (en) * | 1995-09-26 | 1997-04-17 | Shionogi & Co., Ltd. | Novel sulfonamide compounds and medicinal composition |
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| DE19540737A1 (de) * | 1995-11-02 | 1997-05-07 | Bayer Ag | Substituierte Sulfonylamino(thio)carbonylverbindungen |
| US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
| JP2001523218A (ja) * | 1996-02-20 | 2001-11-20 | ブリストル―マイヤーズ・スクイブ・カンパニー | ビフェニルイソキサゾール・スルホンアミドの製造法 |
| US5958905A (en) | 1996-03-26 | 1999-09-28 | Texas Biotechnology Corporation | Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin |
| US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
| US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| AU6187898A (en) * | 1997-01-30 | 1998-08-25 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| SK143399A3 (en) * | 1997-04-28 | 2000-05-16 | Texas Biotechnology Corp | Sulfonamides for treatment of endothelin-mediated disorders |
| US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| MXPA01009362A (es) | 1999-03-19 | 2002-06-04 | Squibb Bristol Myers Co | Metodos para la preparacion de bifenil isoxazol sulfonamidas. |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| ES2273739T3 (es) * | 1999-12-15 | 2007-05-16 | Bristol-Myers Squibb Company | Bifenil sulfonamidas como dobles antagonistas de receptores de endotelina y angiotensina. |
| DK1533311T3 (da) * | 1999-12-31 | 2007-09-17 | Encysive Pharmaceuticals Inc | Sulfonamider og derivater deraf, der modulerer aktiviteten af endothelin |
| CA2348847A1 (en) * | 2000-05-31 | 2001-11-30 | Pfizer Inc. | New isoxazole-sulfonamide endothelin antagonists |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| HU230056B1 (hu) * | 2001-03-12 | 2015-06-29 | Ono Pharmaceutical Co., Ltd | N-fenil-arilszulfonamidok, intermediereik, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| US20090093485A1 (en) * | 2004-10-29 | 2009-04-09 | Astrazeneca Ab | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases |
| WO2007061661A2 (en) | 2005-11-22 | 2007-05-31 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| TW200800150A (en) * | 2005-12-21 | 2008-01-01 | Organon Nv | Compounds with medicinal effects due to interaction with the glucocorticoid receptor |
| AU2007275301A1 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
| TW200829578A (en) | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
| JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
| US20100080786A1 (en) | 2008-05-20 | 2010-04-01 | Markus Berger | Phenyl or Pyridinyl Substituted Indazoles Derivatives |
| CN102348697B (zh) | 2009-01-12 | 2014-12-10 | 辉瑞股份有限公司 | 磺酰胺衍生物 |
| WO2012004706A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| PL3983387T3 (pl) | 2019-06-12 | 2024-08-19 | NodThera Limited | Pochodne sulfonylomocznika i ich zastosowania |
| US20220267300A1 (en) * | 2019-06-12 | 2022-08-25 | NodThera Limited | Sulfonamide derivatives and uses thereof |
| ES3043899T3 (en) | 2019-06-18 | 2025-11-26 | Pfizer | Benzisoxazole sulfonamide derivatives |
| WO2022270487A1 (ja) * | 2021-06-22 | 2022-12-29 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤及び医薬組成物 |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO117180B (pl) * | 1963-12-23 | 1969-07-14 | Shionogi & Co | |
| US3422095A (en) * | 1966-11-04 | 1969-01-14 | Hoffmann La Roche | N**1-and/or n**4-(lower alkoxyacetyl) sulfanilamides |
| US5284828A (en) * | 1990-05-14 | 1994-02-08 | Fujisawa Pharmaceutical Co. Ltd. | Peptide compound and its preparation |
| TW270116B (pl) * | 1991-04-25 | 1996-02-11 | Hoffmann La Roche | |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US5305312A (en) * | 1992-02-07 | 1994-04-19 | At&T Bell Laboratories | Apparatus for interfacing analog telephones and digital data terminals to an ISDN line |
| TW224462B (pl) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc |
-
1993
- 1993-04-20 NZ NZ247440A patent/NZ247440A/en unknown
- 1993-04-21 IL IL10548193A patent/IL105481A/en not_active IP Right Cessation
- 1993-04-26 ZA ZA932914A patent/ZA932914B/xx unknown
- 1993-04-28 JP JP10235493A patent/JP3286391B2/ja not_active Expired - Fee Related
- 1993-04-29 EP EP93303373A patent/EP0569193B1/en not_active Expired - Lifetime
- 1993-04-29 CA CA002095174A patent/CA2095174A1/en not_active Abandoned
- 1993-04-29 DK DK93303373.0T patent/DK0569193T3/da active
- 1993-04-29 ES ES93303373T patent/ES2100459T3/es not_active Expired - Lifetime
- 1993-04-29 AT AT93303373T patent/ATE149155T1/de not_active IP Right Cessation
- 1993-04-29 DE DE69308229T patent/DE69308229T2/de not_active Expired - Fee Related
- 1993-05-04 KR KR1019930007628A patent/KR100277454B1/ko not_active Expired - Fee Related
- 1993-05-04 MX MX9302618A patent/MX9302618A/es not_active IP Right Cessation
- 1993-05-05 NO NO931638A patent/NO303065B1/no not_active IP Right Cessation
- 1993-05-05 PL PL93298828A patent/PL178165B1/pl unknown
- 1993-05-05 AU AU38382/93A patent/AU659545B2/en not_active Ceased
- 1993-05-05 RU RU93004992A patent/RU2133742C1/ru not_active IP Right Cessation
- 1993-05-05 HU HU9301305A patent/HU218938B/hu not_active IP Right Cessation
- 1993-05-06 CN CN93107073A patent/CN1066441C/zh not_active Expired - Fee Related
- 1993-05-06 FI FI932052A patent/FI112655B/fi not_active IP Right Cessation
-
1997
- 1997-05-15 GR GR970401070T patent/GR3023421T3/el unknown
- 1997-06-26 HK HK98197A patent/HK98197A/en not_active IP Right Cessation
-
1998
- 1998-02-20 CY CY201698A patent/CY2016A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2133742C1 (ru) | 1999-07-27 |
| IL105481A0 (en) | 1993-08-18 |
| DE69308229T2 (de) | 1997-07-17 |
| NO303065B1 (no) | 1998-05-25 |
| FI932052L (fi) | 1993-11-07 |
| NZ247440A (en) | 1995-04-27 |
| FI932052A0 (fi) | 1993-05-06 |
| JPH0649046A (ja) | 1994-02-22 |
| MX9302618A (es) | 1994-05-31 |
| HU9301305D0 (en) | 1993-09-28 |
| HK98197A (en) | 1997-08-08 |
| ZA932914B (en) | 1993-11-12 |
| CN1084515A (zh) | 1994-03-30 |
| KR930023337A (ko) | 1993-12-18 |
| HU218938B (hu) | 2001-01-29 |
| EP0569193B1 (en) | 1997-02-26 |
| AU3838293A (en) | 1993-11-11 |
| NO931638D0 (no) | 1993-05-05 |
| AU659545B2 (en) | 1995-05-18 |
| JP3286391B2 (ja) | 2002-05-27 |
| EP0569193A1 (en) | 1993-11-10 |
| DK0569193T3 (pl) | 1997-03-17 |
| ES2100459T3 (es) | 1997-06-16 |
| CY2016A (en) | 1998-02-20 |
| NO931638L (no) | 1993-11-08 |
| KR100277454B1 (ko) | 2001-01-15 |
| FI112655B (fi) | 2003-12-31 |
| PL298828A1 (en) | 1993-12-27 |
| PL178165B1 (pl) | 2000-03-31 |
| GR3023421T3 (en) | 1997-08-29 |
| DE69308229D1 (de) | 1997-04-03 |
| ATE149155T1 (de) | 1997-03-15 |
| HUT65751A (en) | 1994-07-28 |
| CA2095174A1 (en) | 1993-11-07 |
| CN1066441C (zh) | 2001-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL105481A (en) | Phenyl isoxazole sulfonamide derivatives and endothelin antagonist pharmaceutical compositions containing the same | |
| US6107320A (en) | Phenyl sulfonamide endothelin antagonists | |
| US6080774A (en) | Substituted biphenylsulfonamide endothelin antagonists | |
| AU720458B2 (en) | Substituted biphenyl isoxazole sulfonamides | |
| KR100257134B1 (ko) | 술폰아미드 엔도텔린 길항제 | |
| NZ264319A (en) | Pyridazine-3-sulphonamide derivatives; preparation and pharmaceutical compositions | |
| NZ272812A (en) | N-oxazolyl azolyl(alkyl)biphenylsulphonamide derivatives; pharmaceutical compositions | |
| US6673824B1 (en) | Phenyl sulfonamide endothelin antagonists | |
| AU717230B2 (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
| EP1328523A2 (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
| US5856507A (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
| CA2367916A1 (en) | Methods for the preparation of biphenyl isoxazole sulfonamides | |
| RU2209815C2 (ru) | Способы получения бифенилизоксазолсульфонамидов | |
| HK1002391A (en) | N-pyridazinyl-benzene ( naphthalene-, biphenyl- ) sulfonamide derivatives, their preparation and their use as endothelin antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |